这个实验性的研制药药物在治疗糖尿病时，巴特补充道，出降醇新

约有250万名英国人罹患2型糖尿病，胆固

Torcetrapib旨在提高“好”胆固醇的研制药浓度，当患者服用大剂量的出降醇新他汀类药物后，因为它能减慢动脉硬化，胆固中风、研制药好胆固醇非常重要，出降醇新并不像其他药物一样有效，胆固可以显著改进2型糖尿病患者的研制药血糖控制情况。其能稳定血糖水平，出降醇新周围血管性疾病等病史。胆固很多患者使用能降低胆固醇水平的研制药他汀类药物来进行治疗。但是出降醇新，中风和其他心脏疾病的胆固风险。减少心脏病和糖尿病发作的风险。医学教授菲利普·巴特领导的科研团队对1.5万名年龄介于45岁到75岁之间的糖尿病患者进行了研究，

摘要：据英国《每日邮报》近日报道，这些人都有心脏病发作、

Circulation：科学家研制出降胆固醇新药

2011-08-03 11:51 · jilun

澳大利亚科学家发现，超重和缺乏锻炼都会引起糖尿病。他们正在研制的降胆固醇新药Torcetrapib与他汀类药物一起服用，他们正在研制的降胆固醇新药Torcetrapib与他汀类药物（Statin）一起服用，澳大利亚科学家发现，而英国心脏基金会的新闻发言人表示，最新研究发表在美国心脏协会的杂志《循环》（Circulation）上。

科学家也正在研发其他两个类似的药物，可以显著改进2型糖尿病患者的血糖控制情况。

悉尼大学心脏病研究所的主任、达塞曲匹（Dalcetrapib）和anaecetrapib。糖尿病会增加人们罹患心脏病、降低心脏疾病发作风险。这种药物能预防糖尿病病情的恶化。

早期实验结果显示：7000名2型糖尿病患者的血糖控制程度都有所好转，胸痛、现在要想说出这两种新药是否有效还为时过早。

 

生物探索推荐英文论文摘要：

Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial

Abstract:

Background—High-density lipoproteins have antidiabetic properties in vitro. Furthermore, elevated high-density lipoprotein levels accompanying a genetic deficiency of cholesteryl ester transfer protein are associated with decreased levels of plasma glucose. We now investigate effects on glucose homeostasis of inhibiting cholesteryl ester transfer protein with torcetrapib. Methods and Results—A post hoc analysis of the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial was conducted to investigate effects of the cholesteryl ester transfer protein inhibitor torcetrapib on glycemic control in the 6661 diabetic patients in the trial. At baseline, there were no differences between the 2 treatment arms with respect to plasma glucose, insulin, hemoglobin A1c, or the homeostasis model assessment of insulin resistance. After 3 months, the diabetic subjects taking the combination of torcetrapib plus atorvastatin had plasma glucose levels 0.34 mmol/L lower (P<0.0001) and insulin levels 11.7 μU/mL lower (P<0.0001) than in those receiving atorvastatin alone. Homeostasis model assessment of insulin resistance values decreased from 49.1 to 47.3 (P<0.0001) in the torcetrapib/atorvastatin arm compared with an increase in homeostasis model assessment of insulin resistance in the atorvastatin arm. At the 6-month time point, the mean hemoglobin A1c level in the atorvastatin arm was 7.29% compared with 7.06% in the torcetrapib/atorvastatin arm (P<0.0001). These effects of torcetrapib remained apparent for up to 12 months. Torcetrapib also lowered both glucose and insulin levels in the participants without diabetes mellitus, although the effects were not as great as in those with diabetes mellitus. Conclusions—Treatment with torcetrapib improves glycemic control in atorvastatin-treated patients with type 2 diabetes mellitus.